HUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
January 13, 2025 23:00 ET | Source: HUTCHMED (China) Limited — Indication…
HUTCHMED Announces US$608 million Divestment of Non-Core JointVenture
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to…
HUTCHMED Announces US$608 million Divestment of Non-Core JointVenture
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to…
HUTCHMED to Receive Milestone Payment from Takeda following FirstEuropeanReimbursement for FRUZAQLA (fruquintinib)
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in…
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE…
HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTerms
November 28, 2024 05:30 ET | Source: HUTCHMED (China) Limited HONG KONG…